South Africa

Cipla has bolstered its ophthalmology portfolio and increased its global offering after chalking up an agreement to add Formosa Pharmaceuticals’ USFDA-approved clobetasol propionate 0.05% ophthalmic suspension.

South Africa’s Aspen Pharma has discussed the “significant progress” it believes it has made in GLP-1s, with an eye on rolling-out semaglutide in non-US and non-EU markets beginning as early as 2026.

South Africa’s Adcock Ingram struck a downbeat tone during its financial first-half results call, as multiple factors conspired to produce a performance “well below expectations.”

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Lupin has added two ADHD drugs to its Canadian portfolio, while also signing multiple branded deals in other global markets.

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.

Generics Bulletin recaps the most recent regulatory news from across the world.

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Pointing to capacity constraints and an ever-increasing global demand, Aspen has trumpeted its prospects in GLP-1s after striking a deal that could have a significant impact for the firm, both commercially and from a manufacturing standpoint.

South Africa’s Adcock Ingram welcomed 11 new product launches during its most recent financial year, as it battled on multiple fronts to maintain and ratchet up capacity at its local manufacturing facilities.